While 4D Molecular Therapeutics Inc has overperformed by 2.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FDMT fell by -85.81%, with highs and lows ranging from $28.93 to $2.23, whereas the simple moving average fell by -59.11% in the last 200 days.
On January 13, 2025, BMO Capital Markets Downgraded 4D Molecular Therapeutics Inc (NASDAQ: FDMT) to Market Perform. A report published by Morgan Stanley on November 21, 2024, Initiated its previous ‘Underweight’ rating for FDMT. Barclays Initiated an Overweight rating on April 15, 2024, and assigned a price target of $459. Barclays initiated its ‘Overweight’ rating for FDMT, as published in its report on April 15, 2024. Goldman’s report from February 07, 2024 suggests a price prediction of $81 for FDMT shares, giving the stock a ‘Buy’ rating. RBC Capital Mkts also rated the stock as ‘Outperform’.
Analysis of 4D Molecular Therapeutics Inc (FDMT)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
To gain a thorough understanding of 4D Molecular Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. Taking into account the quick ratio of the company, currently set at 14.92, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and FDMT is recording an average volume of 811.48K. On a monthly basis, the volatility of the stock is set at 10.16%, whereas on a weekly basis, it is put at 7.08%, with a gain of 5.85% over the past seven days. Furthermore, long-term investors anticipate a median target price of $32.09, showing growth from the present price of $3.44, which can serve as yet another indication of whether FDMT is worth investing in or should be passed over.
How Do You Analyze 4D Molecular Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 14.40%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 91.88% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
FDMT shares are owned by institutional investors to the tune of 91.88% at present.
